Introduction
The majority of multiple myeloma patients develop bone lesions at some stage of their disease. According to the guidelines of the International Mye loma Working Group (IMWG), skeletal surveys have been considered the gold standard imaging modality for many years [1] . Unfortunately, this technique is insufficiently sensitive to detect early lesions or monitor treatment re sponses. A revision of the IMWG guidelines introduced magnetic resonance imaging (MRI) into routine clinical practice, but positive positron emission tomography (PET) alone remains insufficient to diagnose active myeloma [2] . In contrast to skeletal surveys and computed tomography (CT), PET com bined with CT (PET/CT) allows for direct, noninvasive visualisation of the tumour burden [3] . PET/CT using fluorinelabelled deoxyglucose (2deoxy 2[
F]fluoroDglucose [
18 FFDG] PET/CT) can be more effective than a skele tal survey in upstaging patients with suspected smouldering myeloma [4, 5] . On the other hand, 18 FFDG PET/CT can be equivocal and difficult to interpret in some patients with a new diagnosis. For this reason, the main indication for 18 FFDG PET/CT is currently evaluating and monitoring response to ther apy [6] . Fluoroethyltyrosine ( 18 FFET) is an amino acid tracer used in the diagnosis of brain tumours [7, 8] . Myeloma cell lines have the ability to trans port and partially metabolise 18 FFET [9] . Similarly to 11 Cmethionine, 18 FFET is not only taken up but also is incorporated into newly synthesised proteins [9, 10] . It can be of special interest while visualisation of plasma cell mass is a target. The aim of this study was to analyse the metabolism of 18 FFET tracer in vivo, in both the active phases of multiple myeloma and in patients who have responded to chemotherapy, to assess the potential utility of the application of 18 FFET in the clinical setting.
Material and methods
This study was conducted between 2014 and 2017. Thirtytwo patients were included (Table 1) . There were eight patients with newly diagnosed active myeloma, nine with previously treated disease in plateau phase (one in complete remission [CR] and eight in very good partial remission [VGPR] after firstline treatment), and 15 with active, relapsed disease. 
FET -fluoro-ethyl-tyrosine, CT -computed tomography, VGPR -very good partial remission, CR -complete remission
Patients were diagnosed as follows: 14 with IgG myeloma, followed by 11 with light chain disease and seven with IgA type, 16 with κ light chain, and 16 with λ. Among treat ed patients the median number of previous chemotherapy lines was two (range one to five), and seven patients had autologous stem cell transplant (Table 1) . Only patients with VGPR or CR were included in the inactive myeloma group assessment [11] . The clinical evaluation was based on the following: physical examination, bone marrow as pirate or trephine assessment, blood count, concentration of monoclonal protein and free light chains in serum and urine, serum levels of creatinine, calcium, albumin, and β2 microglobulin. Each complete remission (disappear ance of monoclonal protein on immunofixation or Bence Jones protein on 24hour urine collection) was histologi cally confirmed by trephine biopsy according to uniform criteria. Patients were not routinely explored by MRI un less surgical local procedure on the spine was considered. MRI tests were usually done after initiation of the treat ment, so they could not be compared with PET/CT results.
Whole body imaging with 18 
F-FET PET/CT
Patients fasted for at least four hours before the ad ministration of 18 FFET tracer, in order to maintain similar test conditions. The examinations were performed using Biograph mCT128 or Biograph mCT 20 scanners. All partic ipants underwent whole body imaging in two steps: first from the top of the skull to the upper third of the thigh and then from the upper quarter of the thigh down to the feet. Patients received 350 ± 10 MBq of 18 FFET intravenously. The time between the injection and acquisition was 60 min utes. Acquisition of the trunk image was performed with the patient's arms arranged alongside the body. The CT scan was acquired with the following parameters: Care Dose 4D, 120 kV, and pitch 0.8 or 0.7 depending on the scanner. The CT scan was acquired during shallow breathing. The PETscan was acquired with an acquisition time of 2.7 mi nutes per bed position. The total acquisition time was ap proximately 50 minutes depending on the height of the patient. The CT data were used for attenuation correction. Images were reconstructed using a commercial threedimen sional iterative reconstruction algorithm called TrueX+tof (UltraHDPET; 200 × 200 matrix, 3mm intervals, three iter ations, 21 and 24 subsets). The standardised uptake value (SUV max ) for each lesion was calculated on PET images using the wholebody lowdose CT as a reference. To compare the metabolic activity of 18 FFET in areas affected by MM with unaffected regions, several "background" areas of the body were tested: the Th10 and L4 vertebrae and the spleen, the brain, and the left gluteus maximus muscle. To assess the physiological activity in these organs SUV max values were calculated. During the PET examination, the result was con sidered positive when focal myeloma infiltration, defined as circumscribed areas of high 18 FFET PET metabolism with a corresponding bone or soft tissue change, was found. The SUV max values of the background areas were calculated in volume of interest (VOI) 5 cm 3 ±10%. These regions were chosen according to observation of the wholebody PET. These areas were most stable and assured enough space to create VOIs as stated above. Each case was evaluated inde pendently by two experienced nuclear medicine specialists working independently (BM, RL), as well as by an experi enced radiologist.
Sensitivity The study was performed in accordance with the prin ciples of the Helsinki Declaration and was based on the approval given by the local Bioethical Committee. Each participant signed an informed consent form to partici pate in the study.
Results
Because histological proof could not be obtained for every lesion, lowdose CT served as a standard of reference in this study. Focal lesions were found on CT in 29 of 32 pa tients (91%). In total, 518 lesions were found (median 6, range 1-68; Table 1 ). Foci described as positive presented significant enhanced 18 FFET uptake. In all patients with multiple lesions the metabolic activity (SUV max ) in the background areas, apart from the spleen, was lower than the lowest SUV max value in pathologically involved areas. The only exceptions were two patients in whom one lesion had a value lower than one background area, but the activ ity inside the lesion was clearly higher than in surrounding tissue. In total, 129 18 FFETpositive lesions were found in 22 of 32 patients (69%), with a median of 3 (range: 1-28). The mean SUV max of focal osteolytic 18 FFETpositive lesions was 3.45 (range: 1.9-6.2) in comparison to the mean SUV max of the background: brain 1.15 (range: 0.6-1.8; p < 0.00004), the mean SUV max of the spleen was 2.15 (range: 1.7-3.4; p < 0.00008), the mean SUV max of the spine at Th10 was 1.90 (range: 1.2-3.7; p < 0.00005), the mean SUV max of the spine at L4 was 1.80 (range: 1.1-4.9; p < 0.00005), and mean SUV max of the gluteus muscle was 1.75 (range: 1.4-2.3; p < 0.00001) ( Table 2 ). In total, 129 lesions were visible on 18 FFET and 518 lesions on CT. The sensitivity of the 18 FFET/CT assessment was 55.58% (95% CI: 52.31-58.80%), specificity was 9.09% (95% CI: 1.12-29.16%), PPV was 96.28% (95% CI: 95.23-98.55%), and the negative pre dictive value was 0.48% (95% CI: 0.13-1.78%).
From the myeloma activity point of view, three groups could be discriminated: those with newly diagnosed ac tive myeloma (eight patients); myeloma patients with confirmed VGPR or CR after treatment (nine patients), and those with active disease after relapse (15 patients). On CT scans, lesions were found in all patients with newly diag nosed disease (median 5, range: 1-22), in all but two pa tients from the second group (median 5, range: 1-68), and in 14 patients with relapsed myeloma (median 8, range: 1-52; Figs. 1-3 ; Table 1 ).
All but one patient with active disease (group 1 and group 3) had 18 FFETpositive lesions (median 3, range: 1-28). In patients from group 1 with newly diag nosed mye loma, 64 lesions were found on CT and 83 on 18 FFET. In six patients, the number of lesions on CT and 18 FFET was the same, and two had more lesions on 18 FFET than on CT (Table 1 ). In this subgroup the sensitivity of 18 FFET was 100% (95% CI: 96.65-100%), specificity was 9.09% (1.12-29.16%), and PPV was 80.58% (95% CI: 78-82.57%).
Patients with CR and VGPR had no FETpositive lesions. One of the patients in CR, according to the assessment of the treating physician, had an equivocal lesion on CT, which was positive on standard PET with fluorinelabelled deoxyglucose (2deoxy2[ FFET tracer did not reveal any activity (Fig. 4) . Obviously, the bi opsy of the affected area could not be performed.
From 15 patients with active relapsed myeloma (group 3), 47 FETpositive lesions were found in 14 of them (median 3, range: 1-8). CT assessment of the same group showed 282 lesions in 14 patients (median 9.5, range: 1-58). One of the patients had soft tissue mass (soft palate) with in creased FET activity and with no visible lesions on CT.
The sensitivity of the test was 54.44% (95% CI: 50.04-58.79%), specificity was 66.67 % (95% CI: 9.43-99.16%), and the PPV was 99.65% (95% CI: 98.27-99.93%). 
Discussion
Numerous studies have shown the usefulness of 18 FFDG PET/CT in the diagnosis of bone disease in patients with myeloma [12] . In a prospective study designed to compare 18 FFDG PETCT with wholebody Xray (WBXR) and MRI, the latter was shown to be the most sensitive in the detection of diffuse bone marrow involvement, but PET/CT provided additional and valuable information for the assessment of myeloma bone disease in areas not covered by MRI and WBXR [13, 14] . In a systematic review of eight studies, in cluding 798 patients, and comparing 18 FFDG PET/CT with WBXR and MRI, a higher sensitivity of FDG PET in the detec tion of myeloma bone lesions was shown in six studies [15] . Other reviews confirmed no difference between 18 FFDG PET/CT and MRI in the detection of myelomarelated bone disease in terms of sensitivity and specificity [3, 16] . The IMWG updated criteria for diagnosis of multiple mye loma says that increased uptake on PET/CT alone is not adequate for diagnosis of myeloma [2] . The reason for this is the possibility of false positive and false negative results [17, 18] . There are multiple reasons for false posi tivity of 18 FFDG PET, including: inflammation or infection, bone remodelling, recent chemotherapy or radiotherapy, or growth factor support; and for false negativity: hyper Table 2 . Cont. glycaemia, recent administration of highdose steroids, or the presence of subcentimetre lytic lesions close to the brain [6] . As yet, no consensus has been reached regarding an appropriate SUV max cutoff value to distinguish positive and negative readings [19] .
In order to individualise and improve patients' manage ment there is an obvious need to develop a novel tracer. In an attempt to find such a tracer some research groups focused on a characteristic feature of plasma cells -ex cessive production of immunoglobulin particles and used amino acid labelled with radioisotopes, such as methio nine labelled with carbon ( 11 CMET, which is used in the diagnosis of a wide range of cancers. In preliminary myeloma studies it was found that the uptake of 11 CMET exceeds that of 18 FFDG by 1.5 to 5fold [9, 20] .
Luckerath et al. evaluated the radiotracers 11 CMET and 18 FFDG, on myeloma cells, to monitor the response to antimyelomatherapy, and for outcome prediction [10] . 11 CMETuptake, but not 18 FFDG, significantly decreased after a bortezomib injection to myeloma cell lines. Early reduction of 11 CMET correlated with improved survival in mice.
Usefulness of 11 CMET in a clinical scenario was de scribed by Nakamoto et al., who compared 11 CMET and 18 FFDG in vivo using this tracer to analyse 20 patients (six patients with active myeloma and 14 after the treatment) [21] . All the results were compared between the two scans.
11
CMET uptake tended to be higher and more lesions of grade 3 or 4 were depicted by 11 CMET than by 18 FFDG PET/CT. The patientbased sensitivity, specificity, and accu racy of 11 CMET for restaging were 89%, 100%, and 93%, re spectively, while those of FDG were 78%, 100%, and 86%, respectively [21] .
Recent results were published by Lapa et al., who pre sented 43 patients with myeloma, who underwent both MET and FDGPET/CT for staging or restaging [22] . Eleven of them had a new disease, and 32 had been pretreated with various numbers of chemotherapy regimens. Scans were compared regarding patients and lesions. Both trac ers correlated with a degree of plasma cell bone marrow involvement and clinical parameters reflecting disease ac tivity with 11 CMET demonstrating a stronger correlation.
CMET was also superior in staging and restaging intra and extramedullary bone lesions.
Okasaki Ffluorocholine (FCH) [23] [24] [25] [26] . All of them required fur ther investigations.
In contrast to the above, very little is known about 18 FFET in the setting of multiple myeloma bone disease. For 18 FFET PET/CT cyclotron onsite is not necessary; it can be implemented in every centre using PET/CT, but the data from cell lines suggests that the relative uptake of ¹¹CMET exceeds that of 18 FFET 7 to 20fold [9] . In our study, we tried to assess the sensitivity and positive predictive value FFET in detecting mye lomarelated lesions using CT as a standard of reference.
A mismatch between PET/CT with 18 FFDG as a tracer and anatomic imaging modalities, regarding demonstra tion of myeloma lesions, was described by Caers et al. [3] . It confirmed that standard lowdose CT is not capable of discriminating between vital and fibrotic myelomarelated lesions [27] .
Focal lesions may remain positive on CT or hyper intense on MRI for several months after treatment, in re sponding or nonresponding patients, because of treat mentinduced necrosis or inflammation [28] , which could be an explanation for the difference between the number of lesions observed in CT and in FET in patients previous ly treated and being in plateau or with recurrence of the disease in our patients. On the other hand, in untreated patients from our cohort the number of observed lesions on 18 FFET PET/CT was higher than on standard CT, which might suggest a possible increased sensitivity of our tracer in the detection of active disease. Our hypothesis is that high 18 FFET uptake reflects activity of the plasma cell pro duction.
Association between intracellular Ig light chains with MET uptake was already reported by Luckerath et al. [9] . The presence of myelomarelated bone disease, reflected by positive lesions on CT, is a secondary event. It can ex plain why 18 FFETpositive lesions were found in areas neg ative on CT in patients with primary or secondary active disease but not in patients in CR or VGPR.
We hope that 18 FFET tracer will be able to overcome the weaknesses of PET/CT based on 18 FFDG. A lack of ac tivity in the patient with complete remission can suggest better specificity of 18 FFET than standard 18 FFDG PET/CT. It is possible that 18 FFET PET/CT is capable of patients with active disease, which we saw in the group of patients with newly diagnosed myeloma. Because of the small co hort of patients in our study the presented results require further validation.
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